Skip to main content
SpringerLink
Log in

Okuläre Pharmakokinetik

Topische, intravitreale und systemische Medikamentengabe

Ocular pharmacokinetics

Topical, intravitreal, and systemic drug application

  • Einführung zum Thema
  • Published:
Der Ophthalmologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Kroll P, Meyer CH (2006) Which treatment is best for which AMD patient? Editorial. Br J Ophthalmol 90:128–130

    Article  CAS  PubMed  Google Scholar 

  2. Lai JC, Lapolice DJ, Stinnett SS et al (2002) Visual outcomes following macular translocation with 360-degree peripheral retinectomy. Arch Ophthalmol 120:1317–1324

    Article  PubMed  Google Scholar 

  3. Michels S, Rodrigues EB, Meyer CH et al (2011) Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections. Acta Ophthalmol 89:70–75

    Article  PubMed  Google Scholar 

  4. Holz FG, Korobelnik JF, Lanzetta P et al (2010) The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci 51:405–412

    Article  PubMed  Google Scholar 

  5. Laude A, Tan LE, Wilson CG et al (2010) Intravitreal therapy for neovascular age-related macular degeneration and inter-individual variations in vitreous pharmacokinetics. Prog Retin Eye Res 29:466–475

    Article  CAS  PubMed  Google Scholar 

  6. Krohne TU, Liu Z, Holz FG, Meyer CH (2012) Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol 154:682–686

    Article  CAS  PubMed  Google Scholar 

  7. Stewart MW, Rosenfeld PJ, Penha FM et al (2012) Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina 32:434–457

    CAS  PubMed  Google Scholar 

  8. Sakanaka K, Kawazu K, Tomonari M et al (2008) Ocular pharmacokinetic/pharmacodynamic modeling for multiple anti-glaucoma drugs. Biol Pharm Bull 31:1590–1595

    Article  CAS  PubMed  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. Offenlegung potenzieller Interessenkonflikte (Kategorie 1: Unterstützung von Forschungsprojekten und klinischen Studien; Kategorie 2: Beratung, Honorare, Reisekosten). T.U. Krohne – Kategorie 1: Alcon, Novartis; Kategorie 2: Bayer, Heidelberg Engineering, Novartis. C.H. Meyer – Kategorie 1: Novartis, Allergan; Kategorie 2: Bayer, GSK, Novartis. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Klinik Pallas AG, Bahnhofplatz 4, 5000, Aarau, Schweiz

    C.H. Meyer

  2. Universitäts-Augenklinik Bonn, Ernst-Abbe-Str. 2, 53127, Bonn, Deutschland

    T.U. Krohne

Authors
  1. C.H. Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T.U. Krohne
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to C.H. Meyer or T.U. Krohne.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meyer , C., Krohne, T. Okuläre Pharmakokinetik. Ophthalmologe 111, 104–106 (2014). https://doi.org/10.1007/s00347-013-2930-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00347-013-2930-y

Search

Navigation